Evidence Hub

Perspectives on cardiovascular biomarkers: one fits all biomarkers are out, personalization is in

M. Möckel

Biomarkers, 2023

1 citation

Abstract

in this issue of Biomarkers, 8 exceptional abstracts of the “17th annual Biomarkers and Personalised Medicine in Cardiovascular disease Symposium” are published [https:// doi.org/10.1080/1354750X.2023.2205221]. these abstracts reflect current trends in cardiovascular biomarkers clinical needs and topics including markers of cardiac injury and infarction (abstracts no. 1, 2 and 6), of contrast nephropathy (abstract no. 3), of arrhythmias (abstract no. 4 and 8), acute heart failure (abstract no. 5) and infection (abstract no 7). it is noteworthy that despite the fact that the actual guidelines of the European Society of Cardiology (ESC) do not support other biomarkers than cardiac troponin for the assessment of patients with suspected acute coronary syndrome (aCS) (Collet et al., 2020) Cepin et al. (abstract no. 6) highlight with two instructive case reports that CK-MB may close unmet needs of high-sensitive troponin (hstn) although CK-MB is thought to be of no benefit any more (Jaffe et al., 2021). the authors highlight that in patients with concomitant disease like renal failure and in late presenters, CK-MB dynamics help to be more precise in individual decision making than cardiac troponin alone. Wong et al. (abstract 1) found that there are relevant “Ethnic differences in High-Sensitivity Cardiac troponin t among Patients with Chest Pain in the Emergency department” leading to under-diagnosis of acute myocardial infarction among asians. in summary, both abstracts…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free